Find A Clinical Trial

Disease Type: Esophageal/Gastric

Trial ID AT148006
Sponsor ID ASPEN-06

A PHASE 2/3 STUDY OF ALX148 IN PATIENTS WITH ADVANCED HER2-OVEREXPRESSING GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (ASPEN-06)

Principal Investigator
Samuel Lee, MD
Trial ID SGN-PDL1V
Sponsor ID SGNPDL1V-001

A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors

Trial ID MCLA-129
Sponsor ID MCLA-129-CL01

Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Trial ID HFB-200603
Sponsor ID HFB-200603-01

A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200603 (Anti-BTLA Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors

Trial ID CBP-1019
Sponsor ID CBP-1019-101

An Open-Label, Non-randomized, Multinational, Multi-center Phase I/Ⅱ Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

Trial ID BBI-355
Sponsor ID BB-1701-101

An Open-Label, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination With Select Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Oncogene Amplifications

Trial ID ABBV400
Sponsor ID M21-404

A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 in Adult Subjects With Advanced Solid Tumors

Trial ID Arcus Star-221
Sponsor ID Arcus Biosciences

A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma

Principal Investigator
Keeran R. Sampat, MD
Trial ID ARC-21
Sponsor ID Arcus Biosciences

A safety and efficacy study of domvanalimab + zimberelimab combination therapy with and without chemotherapy in adult participants with advanced upper gastrointestinal tract malignancies

Principal Investigator
Keeran R. Sampat, MD